FDA Determines Regulatory Review Period for LATUDA Patent Extension

Summary

The Food and Drug Administration (FDA) has officially announced the regulatory review period for LATUDA, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.